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A b s t r A c t
The central role of platelets in acute coronary syndromes (ACS) and percutaneous 
coronary interventions (PCI) is well appreciated. The various platelet activation 
mechanisms finally lead to the expression and activation of surface glycoprotein IIb/
IIIa receptors that mediate platelet aggregation and thrombus formation. Glycopro-
tein IIb/IIIa inhibitors (GPIs) are the most potent antiplatelet agents and their role 
in ACS treatment and PCI has been dominant in the recent past. The advent of st-
ents and thienopyridines minimized ischemic complications and in parallel the role 
of GPIs in low risk PCI. Despite being effective in decreasing PCI-related ischemic 
complications, the major drawback of GPI use is a relative increase of hemorrhagic 
complications that can unfavorably affect prognosis. The availability of bivalirudin, 
which is regarded as an equally effective but safer antithrombotic agent when com-
pared to the combination of heparin and GPIs, despite an ongoing controversy, has 
also led to a decrease of GPI use in PCI for ACS. Finally the advent of novel potent 
antiplatelet agents (prasugrel, ticagrelor and soon cangrelor) further contained GPI 
use in patients with ischemic – thrombotic risk that clearly exceeds bleeding risk and 
mainly for bail-out in case of a thrombotic event during PCI. A concise overview of 
accumulated data regarding optimal use of GPIs as determined by large clinical trials 
and recent guidelines is herein attempted.
I N t r O D U c t I O N
The glycoprotein IIb/IIIa receptor is an integrin, a heterodimer consisting of αIIb 
and β3 subunits, which mediates the final common pathway of platelet aggregation. 
Glycoprotein IIb/IIIa inhibitors (GPIs) compete with fibrinogen and von Willebrand 
factor for glycoprotein IIb/IIIa binding and thus interfere with platelet cross-linking 
and platelet-derived thrombus formation (Fig. 1). Due to this mechanism of action, 
GPIs are very effective in inhibiting platelets and three parenteral GPIs with different 
pharmacologic features have been approved for clinical use: abciximab, eptifibatide, 
and tirofiban (Table 1).
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tAble 1. Pharmacologic properties of Glycoprotein IIb/IIIa inhibitors (GPIs).
Αbciximab Eptifibatide Tirofiban
Molecule Fab 7E3 Synthetic peptide Non-peptide mimetic
Binding Non competitive Competitive Competitive
Half-life
Plasma: 10 - 15 h Plasma: 2 - 2.5 h Plasma: 2 - 2.5 h
Biologic: 12 - 24 h Biologic = plasma Biologic = plasma
PCI dosing
Bolus: Bolus: Bolus:
0.25 mg/kg 180 µg/kg (10 min) + 180 µg/kg 25 µg/kg
Infusion: Infusion: Infusion:
0.125 µg/kg/min (12 h)
Max: 10 µg/min
2 µg/kg/min (24 to 48 h) 0.15 µg/kg/min (18 h)
Renal adjustment No
Bolus: Bolus:
180 µg/kg 12.5 µg/kg
Infusion: Infusion:
1 µg/kg/min (24 to 48 h) 0.075 µg/kg/min (18 h)
PCI = percutaneous coronary intervention
FIgUre 1. Schematic representation of glycoprotein IIb/IIIa receptors and inhibitors.
GP IIb/IIIa receptors and inhibitors
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Glycoprotein IIb/IIIa inhibitors (GPIs) became widely 
accepted into the standard of care for percutaneous coronary 
intervention (PCI) during the 90’s, especially in the setting 
of acute coronary syndromes (ACS), as a strategy to reduce 
ischemic complications with a noteworthy clinical benefit.1-4 
Although rates of short-term ischemic complications were as 
high as 10-13% in patients receiving only aspirin and intra-
procedural heparin during PCI, the addition of GPIs reduced 
that risk by as much as 50% and long-term mortality by nearly 
20%.3,5 However, since platelet inhibition is particularly intense 
with GPIs, their use is linked to increased rates of bleeding 
complications.6,7 Such events are associated with prolonged 
hospital stay, increased costs, can unfavorable impact mortal-
ity and should be prevented, that is why the use of GPIs has 
not always been broad but cautious and somehow limited.8,9 
Improvements in interventional tools (such as minimally 
thrombogenic thinner-strut stent designs) and pharmaco-
therapy (such as early administration of P2y12 receptor antago-
nists to patients with ACS and/or those undergoing PCI and 
introduction of the more potent P2y12 inhibitors, prasugrel and 
ticagrelor) have remarkably enhanced the safety and efficacy 
of PCI.10-13 Thus, progressively the balance of benefit versus 
risk with GPIs changed and their diminished role is reflected in 
current PCI guidelines.14 An overview of the gradual changes 
in GPI use over time, as affected by advances of interventional 
pharmacotherapy and until reaching their current role is at-
tempted in this paper.
t h e  e r A  b e F O r e  c l O p I D O g r e l
before the era of pretreatment with clopidogrel loading 
doses, the safety and efficacy of GPIs was tested in several 
clinical studies that included patients with both ACS and stable 
coronary artery disease (CAD). EPIC was the landmark trial 
that demonstrated the efficacy of GPIs in the PCI setting.1 In 
this study, high-risk patients undergoing balloon angioplasty 
were randomized to abciximab bolus and infusion, abciximab 
bolus alone or placebo. No significant benefit with abciximab 
bolus alone was observed while the group treated with abcixi-
mab bolus and infusion had a 35% lower rate of death, myo-
cardial infarction (MI), or unplanned urgent revascularization 
at 30 days compared with the placebo group. Major bleeding 
complications occurred in a very high proportion of patients 
treated with abciximab.1 EPILOG was another landmark trial 
that was conducted in patients undergoing balloon angioplasty 
who were at a lower risk than the patients in EPIC.2 In EPI-
LOG, abciximab was given with weight-adjusted infusions and 
was combined with lower doses of weight-adjusted heparin. 
This study showed a significant reduction in the incidence of 
death or MI in patients treated with abciximab with acceptable 
bleeding rates.2 Similar results were reported in the EPIST-
ENT trial. which was the first randomized trial to examine the 
use of a GPI (abciximab) among patients undergoing stent 
implantation.3 The ESPRIT trial conducted in patients under-
going coronary stenting using eptifibatide was terminated early 
because of the superior efficacy of eptifibatide. Major bleeding 
was rare but occurred more frequently in eptifibatide-treated 
patients compared with placebo-treated patients.4,15 Having 
the support of these trials, GPIs became a cornerstone in the 
treatment of patients undergoing PCI because of their ability 
to improve short- and long-term outcomes, mostly by reducing 
the occurrence of peri-procedural MI.
t h e  c l O p I D O g r e l  e r A
With the advent of P2y12 inhibitors it was suggested that 
GPIs may no longer benefit patients if they had been pre-
treated with high-dose clopidogrel, particularly those with 
stable CAD or in the absence of elevated cardiac enzymes. The 
ISAR-REACT trial showed that among low- to intermediate-
risk patients undergoing elective PCI and pretreated for at 
least 2 hours with a 600-mg loading dose of clopidogrel, 
no benefit of abciximab therapy was found, compared with 
placebo, regarding the incidence of death, MI, and urgent 
target-vessel revascularization at 30 days.16 The findings were 
similar in the ISAR-SWEET trial, a dedicated randomized 
trial to evaluate glycoprotein IIb/IIIa blockade in patients 
with diabetes scheduled for elective PCI.17 Overall, these two 
studies suggest that GPIs offer no clinical benefit in low- to 
intermediate-risk patients scheduled for PCI, including dia-
betics, in case of sufficient pretreatment with clopidogrel.16,17 
The ISAR-REACT 2 trial assessed the incremental benefit 
of GPIs for patients with ACS pretreated with a high load-
ing dose of 600mg clopidogrel at least 2 hours before PCI. 
Included patients were randomized to either abciximab or 
placebo in the catheterization laboratory at the time of PCI. 
Abciximab significantly reduced the incidence of the primary 
end point of death, MI, or target-vessel revascularization at 
30 days, but the benefit of abciximab treatment was limited 
only to those patients who presented with elevated troponin.18 
Overall, these findings suggest that with high clopidogrel 
dosing regimens, GPIs should be reserved only for high-risk 
patients with ACS and elevated cardiac biomarkers and also 
that these agents could be particularly useful in patients 
with substantial thrombus burden, high-risk anatomy, or 
intra-procedural complications in order to reduce ischemic 
complications of PCI.7,18 
t I m I N g  O F  G P I s  A D m I N I s t r A t I O N  
I N  A c s
Two different timing strategies for the administration of 
GPIs have been used in relevant randomized trials: before 
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angiography (upstream treatment) or in the cardiac cath-
eterization laboratory in patients about to undergo PCI (pro-
visional or downstream treatment). These two strategies were 
compared in the EARLy-ACS trial, which randomized 9492 
invasively managed patients with non ST-segment elevation 
ACS (NSTE-ACS) to either routine upstream eptifibatide or 
placebo infusion and provisional eptifibatide after coronary 
angiography. No differences were found between the groups 
regarding the primary ischemic composite end point, while 
patients in the early eptifibatide group had significantly higher 
rates of bleeding and transfusion.7 These findings do not sup-
port the routine use of upstream GPIs compared with ad hoc 
GPIs in patients with NSTE-ACS undergoing PCI.
The use of GPIs, in particular abciximab, in ST-segment 
elevation MI (STEMI) patients undergoing primary PCI is 
supported by a meta-analysis of 11 randomized trials that 
involved a total of 27115 patients. In this meta-analysis, the 
administration of abciximab was associated with a significant 
reduction in the rate of re-infarction, as well as mortality 
rates, at 30 days.19 However, most of the studies included in 
this meta-analysis were conducted in patients who had not 
been pretreated with clopidogrel. In the bRAVE 3 study, 800 
patients with acute STEMI, all of whom were treated with 
clopidogrel 600 mg, were randomly assigned to receive either 
upstream abciximab or placebo. Abciximab was not associ-
ated with a reduction in the primary end point, infarct size, 
or ischemic end points at 30 days, which argued against the 
routine use of upstream abciximab in clopidogrel-pretreated 
patients undergoing primary PCI.20 Apart from abciximab, 
small-molecule GPIs are also commonly used in clinical prac-
tice for STEMI, without existing evidence so far that would 
support their upstream use.21
Strategies of facilitated PCI for STEMI have been devel-
oped based on the principle that time to reperfusion is a critical 
determinant of outcome. In the FINESSE trial, 2452 patients 
with STEMI who presented within 6 hours after symptom onset 
were randomized to receive PCI facilitated with early abcixi-
mab and half-dose reteplase (combination facilitated), PCI 
with early abciximab alone (abciximab facilitated) or primary 
PCI with abciximab at the time of the procedure. The primary 
end point (composite of death from all causes, ventricular 
fibrillation occurring more than 48 hours after randomization, 
cardiogenic shock, and congestive heart failure during the 
first 90 days after randomization) occurred in 9.8%, 10.5%, 
and 10.7% of the patients in the combination-facilitated, 
abciximab-facilitated and primary PCI groups, respectively 
(p = 0.55) without significant differences in mortality. These 
results did not support the use of a facilitated pharmacologic 
strategy for reperfusion, with either abciximab alone or abcixi-
mab plus reduced-dose reteplase, in anticipation of urgent PCI 
for patients who present early with STEMI.22
t h e  A D v e N t  O F  b I v A l I r U D I N  A N D 
h O w  I t  I N t e r F e r e s  w I t h  g p I  U s e
bivalirudin has been studied as an alternative to heparin for 
patients undergoing PCI with stable CAD,23,24 NSTE-ACS,25,26 
and STEMI.27-29 These studies found that bivalirudin reduced 
bleeding complications when compared with regimens of 
heparin plus a GPI by as much as 40%. However, many of 
these trials also found small numerical increases in ischemic 
events with bivalirudin and increases in acute stent thrombosis, 
particularly in patients with STEMI.27,29
Data from the ACUITy trial that included 13819 patients 
with NSTE-ACS randomized to heparin plus a GPI, bivalirudin 
monotherapy or bivalirudin plus a GPI, revealed that ischemic 
outcomes were similar across all three regimens, but bivali-
rudin monotherapy was associated with less major bleeding.25 
In the HORIZONS-AMI trial, bivalirudin monotherapy was 
compared with heparin plus GPI in 3602 patients with STEMI 
undergoing primary PCI. The composite end point of major 
adverse cardiovascular events (death, re-infarction, target ves-
sel revascularization and stroke) occurred at nearly identical 
rates by 30 days in the 2 treatment arms: 5.4% with bivalirudin 
versus 5.5% with heparin plus a GPI, while bivalirudin was 
associated with a 40% reduction in major bleeding and a 34% 
reduction in 30-day mortality. These reductions in bleeding and 
mortality were found despite a significant increase in the risk of 
acute stent thrombosis with bivalirudin, however overall stent 
thrombosis rates did not differ in the two study groups at 30 
days.27 Due to these two landmark trials, bivalirudin has been 
regarded in recent years as a mainstay of anticoagulation in 
ACS patients undergoing coronary intervention, offering sig-
nificant benefits in terms of reduced bleeding events and thus 
supplanted heparin plus GPI during PCI for many patients. 
Over time, the need for routine GPIs for PCI has become 
less evident. Two studies showed that upstream GPI use to 
treat NSTE-ACS increased the risk of bleeding without reduc-
ing ischemic events.7,30 Novel potent P2y12 antagonists have 
also decreased the need for additional GPI use. This change 
of practice is reflected in current guidelines that recommend 
that GPIs should be reserved as bail-out therapy for thrombotic 
complications.14 As a result, there has been a need to reassess 
the efficacy of bivalirudin when compared with heparin, by 
conducting studies in which GPIs are used only on a provisional 
basis in both treatment groups. Following the publication of 
data derived from such studies, controversies have emerged 
regarding the potential of bivalirudin to prevent thrombotic 
complications and its superior safety when compared with 
heparin alone with provisional GPI use.
In accordance with the HORIZONS-AMI findings, the 
recently published EUROMAX trial data in patients with 
STEMI undergoing primary PCI showed that bivalirudin, 
compared with heparin with or without a GPI, significantly 
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reduced the incidence of major bleeding, transfusions, and 
thrombocytopenia. yet, in contrast with the HORIZONS-
AMI, overall cardiovascular mortality did not differ signifi-
cantly. Acute stent thrombosis was still significantly higher 
with bivalirudin regardless of prolonged infusions or the use 
of novel P2y12 inhibitors, whereas stent thrombosis rates at 
30 days did not differ significantly between treatment arms.29
Furthermore, according to current practices, the british 
single center HEAT-PPCI trial randomized 1812 patients with 
STEMI to receive bivalirudin or heparin.31 GPIs were used 
infrequently with bivalirudin (13%) and heparin (15%). In 
contrast with prior trials, there was no difference in bleeding 
and bivalirudin increased the composite end point of death, 
stroke, re-infarction, or unplanned target lesion revasculariza-
tion (8.7% vs 5.7%, p=0.01) and stent thrombosis (3.4% vs 
0.9%, p=0.001).31 
The bRIGHT multi-center trial which was published most 
recently was more supportive for the use of bivalirudin.32 The 
trial was performed in 82 centers in China and randomized 
2194 patients with acute MI undergoing PCI into 1 of 3 open-
label treatment groups: bivalirudin and provisional GPIs, 
heparin and provisional GPIs or heparin and routine GPIs. 
The primary end point was a net adverse clinical end point (a 
composite of death, re-infarction, ischemia-driven revascu-
larization, stroke or any bleeding event). Patients treated with 
bivalirudin and provisional GPIs had lower rates of this net 
composite end point (8.8%) than patients treated with either 
heparin and provisional GPIs (13.2%) or heparin and routine 
GPIs (17.0%). The difference between the groups was almost 
entirely driven by the difference in bleeding. There were no 
differences in ischemic events, including stent thrombosis. Of 
note, the strongest evidence supporting the use of bivalirudin 
in patients with STEMI has been the significant mortality re-
duction with bivalirudin seen in the HORIZONS-AMI trial. 
This finding was not replicated in bRIGHT, where there was 
no signal of mortality reduction with no difference between 
the bivalirudin– provisional GPI and the heparin–provisional 
GPI treatment groups.32 
The results of HEAT-PPCI and bRIGHT are discordant 
but could be explained by the fundamental differences between 
the two trials. Firstly, the studies enrolled different popula-
tions since HEAT-PPCI only included patients with STEMI 
undergoing primary PCI, and bRIGHT randomized patients 
with both STEMI and NSTE-ACS undergoing emergency 
PCI. Secondly, the two trials significantly differed regarding 
the anticoagulation treatment. In the HEAT-PPCI trial, anti-
coagulation was initiated before arrival at the catheterization 
laboratory, whereas in the bRIGHT trial, anticoagulation was 
not administered until patients arrived in the catheterization 
laboratory. The doses of heparin to which bivalirudin and 
provisional GPIs were compared (70 IU/Kg in HEAT-PPCI 
vs 100 IU/Kg in bRIGHT) and the management of bivalirudin 
following PCI (stopped at the end of PCI in HEAT-PPCI with 
increased stent thrombosis vs continued for at least 30 minutes 
or more in bRIGHT without increased stent thrombosis) 
also differed. Finally, the majority of patients in HEAT-PPCI 
received novel potent platelet P2y12 inhibitors, whereas these 
agents were not available in bRIGHT.
bRIGHT has been the third recently published trial 
after EUROMAX and HEAT-PPCI that has evaluated bi-
valirudin in patients with STEMI and has not been able to 
replicate the mortality reduction seen in HORIZONS-AMI. 
Furthermore, in a recent meta-analysis where all of the trials 
in which bivalirudin has been compared with heparin were 
pooled (including bRIGHT), bivalirudin increased the risk 
of ischemic events, reduced the risk of bleeding but there 
was no relationship between the reduction in bleeding and 
death.33 The reduction in bleeding observed with bivalirudin 
was most apparent when it was compared with a regimen 
that included both heparin and a GPI. Similar results were 
found in a network meta-analysis that compared multiple 
anticoagulants used in patients with STEMI.34 In contrast, a 
pooled patient level analysis from the HORIZONS-AMI and 
EUROMAX studies found that primary PCI with bivalirudin 
improved 30-day net clinical outcomes, with significant reduc-
tions in cardiac mortality, major bleeding, transfusions and 
thrombocytopenia, despite increased acute stent thrombosis 
in comparison with heparin with or without GPI.35 However 
the radial approach was used only in 21.3% of patients, prasu-
grel or ticagrelor only in 18.1% of patients, and GPIs were 
used in 84.8% of the control group, numbers that are clearly 
aberrant from current interventional practice.35 Finally, a 
meta-analysis (at study and not patient level) by Navarese et 
al was the largest in the ACS setting to evaluate the 30-day 
safety and efficacy of bivalirudin compared to heparin in 
conjunction with routine or provisional administration of a 
GPI.36 This comprehensive analysis showed that bivalirudin 
treatment resulted in a significant reduction of major bleeding 
as compared with heparin with routinely administered GPI 
but not with provisionally administered GPI. However, it also 
showed that bivalirudin compared with heparin was associated 
with a significant increase in 30-day definite stent thrombosis, 
largely driven by a greater than 4-fold increase in acute stent 
thrombosis regardless of routine or provisional GPI use. 
Moreover it demonstrated that overall mortality or risk of 
MI did not differ significantly, but overall revascularization 
rates were significantly increased with bivalirudin compared 
with heparin. Finally, in concert with the overall analysis, the 
sensitivity analyses of STEMI patients showed a reduction of 
major bleeding compared with heparin plus routine (but not 
with provisional) GPI and increased MI rates mainly attrib-
uted to increased acute (but not subacute) stent thrombosis 
compared with heparin with or without GPI.36
In general, most recent data that followed the initial 
landmark trials in favor of bivalirudin (ACUITy and HORI-
ZONS-AMI) cast some doubt concerning its ability to reduce 
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bleeding if other bleeding prevention strategies are used (such 
as radial approach, heparin at 70-80 IU/kg instead of 100 IU/
kg without GPI use and 50-60 IU/kg with GPI use, activated 
clotting time-ACT monitoring during PCI, provisional and not 
systematic use of GPIs with heparin). Such doubt, combined 
with an alarming signal for increased stent thrombosis with 
bivalirudin found among several relevant studies and without 
forgetting its increased cost, may have already decreased its 
use in favor of heparin with provisional GPI by many inter-
ventional cardiologists.
t h e  A D v e N t  O F  N O v e l  p 2 y 1 2 
A N t A g O N I s t s ,  p r A s U g r e l  
A N D  t I c A g r e l O r
In the TRITON-TIMI 38 trial, prasugrel (an irrevers-
ible, but also fast-acting blocker of the P2y12 receptor) has 
been compared to the hitherto gold standard clopidogrel 
among ACS patients with known coronary anatomy who were 
clopidogrel-naïve and was associated with significantly reduced 
rates of ischemic events with respect to a combined primary 
endpoint (cardiovascular mortality, re-infarction and stroke), 
but not with an overall mortality advantage.13 Prasugrel has 
been shown to be especially effective in diabetic patients, 
high-risk patients with recurrent thrombotic events and in 
reducing stent thrombosis.37 The main side-effect is an increase 
in spontaneous major bleeding events (an absolute increase 
of 0.6%) compared to clopidogrel. It should be avoided in 
patients with prior stroke or transient ischemic attack, in pa-
tients older than 75 years and in underweight patients (<60 
kg) which are subgroups with particularly elevated bleeding 
risk if prasugrel is administered.13 
In the PLATO trial, ticagrelor (a reversible and fast-acting 
ADP-receptor blocker) has been investigated among ACS 
patients (treated primarily invasively as well as primarily 
conservatively) and shown to be superior to clopidogrel with 
respect to the same as in TRITON-TIMI 38 combined primary 
endpoint (cardiovascular mortality, re-infarction and stroke).12 
Of note, ticagrelor has demonstrated a significant reduction of 
all-cause and cardiovascular mortality, which was also shown 
in a pre-specified subgroup analysis for diabetics and patients 
referred for coronary bypass surgery.38,39 Potential side-effects, 
besides an increase in spontaneous major bleeding events (an 
absolute increase of 0.6%), include dyspnea and bradycardia, 
both of which have been associated with the adenosine-like 
properties of the agent.
The two above mentioned trials demonstrated the su-
periority of those two agents among patients with ACS and 
supported their upgraded status over clopidogrel in the most 
recent revascularization guidelines.14 Appropriate utilization 
of third-generation P2y12 antagonists is expected to attenuate 
the incremental benefit of GPIs in ACS with lower risk of 
bleeding and thus their availability contributed to a further 
decrease of GPI use in ACS management.
M E T a - a n a l y s E s  a n d  l a r G E 
r e g I s t r I e s  A s s e s s I N g  G P I s  I N  A c s 
Several meta-analyses and large observational studies 
tried to answer the question of what are the benefits and risks 
when GPIs are used in patients with ACS. In a meta-analysis 
of more than 30,000 patients with ACS (24% of whom un-
derwent PCI), boersma et al found that treatment with GPIs 
led to a 9% reduction in the relative risk of death or MI with 
a concurrent 1% absolute increase in major bleeding.9 More 
recently, Sethi et al performed a meta-analysis of randomized 
trials of GPI use in patients undergoing primary PCI.40 In this 
study of more than 7000 patients, GPI use was associated with 
a 25% reduction in mortality. Meta-regression suggested that 
the benefits of GPIs were confined to patients at highest risk of 
mortality.40 Finally, Winchester et al performed a meta-analysis 
of GPI use in ACS and PCI on the basis of trials performed in 
the contemporary era of stents and dual antiplatelet therapy.41 
Among ACS patients, GPI use was associated with a significant 
reduction in nonfatal MI and an increase in minor bleeding but 
no differences in mortality or major bleeding.41 Thus, although 
there are numerous differences in patient populations, timing 
of drug administration and concomitant medical therapy, most 
studies have tended to demonstrate that GPI use in ACS and 
PCI (particularly in the highest risk patients) leads to modest 
benefits in terms of ischemic complications with a concomitant 
increase in bleeding.
Most recently Safley et al reported the results of an ob-
servational study examining the efficacy and safety of GPI 
in the contemporary interventional management of patients 
with ACS.42 They performed a retrospective analysis of data 
obtained from the National Cardiovascular Data Registry 
of more than 970,000 patients undergoing PCI for an ACS 
between 2009 and 2011. Approximately one-third of these 
patients received GPIs, and the association between GPI use 
and in-hospital mortality and major bleeding was assessed 
with three different methods of statistical adjustment that all 
resulted in very similar hazard ratios for the mortality and 
bleeding endpoints. Thus, GPI use was associated with reduced 
mortality (relative risk ranging from 0.72 to 0.90) and increased 
major bleeding (relative risk ranging from 1.53 to 1.93). GPIs 
were observed to reduce mortality in patients receiving hepa-
rin, but not those treated with bivalirudin. Despite being the 
most recent relevant publication, this study is reflective of 
practices between 2009 and 2011 which differ from current 
ones, since only 5%-7% of patients in this cohort had radial 
artery access and only 11%-12% of patients received third-
generation P2y12 inhibitors, while results were not reported 
for these important subgroups. However, after rigorous data 
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analysis, the authors validly concluded that in the modern 
era of PCI there may still be a role for judicious use of GPI.42 
c U r r e N t  U s e  O F  G P I s  F O r  p c I
1 .  s t A b l e  c O r O N A r y  A r t e r y  D I s e A s e  ( c A D )
Recent trials did not demonstrate additional benefit from 
GPIs after a clopidogrel loading dose of 600 mg.16,43,44 Anecdo-
tal experience, however, suggests that GPIs may be beneficial 
in bail-out situations (intra-procedural thrombus formation, 
slow flow, threatened vessel closure). The REPLACE-2 trial 
demonstrated that outcome with bivalirudin and provisional 
GPI is similar to that of heparin plus planned GPI during PCI 
for stable CAD.23 Subsequently, ISAR-REACT 3, performed 
in patients pre-treated with clopidogrel, showed similar net 
clinical outcomes to bivalirudin and heparin, but heparin 
dosage was higher (140 U/kg) than recommended, leading 
to an excess in major bleeding in patients mostly undergoing 
procedures via femoral access. In view of the primary endpoint 
results and a trend towards a lower risk of MI, anticoagulation 
with heparin with an i.v. bolus of 70–100 U/kg remains the 
standard anticoagulant treatment for elective PCI. Among 
PCI patients with negative biomarkers, bivalirudin reduced 
bleeding without affecting mortality and might therefore be 
considered for use in patients at high risk for bleeding.45
based on the fact that recent trials could not demonstrate 
any additional benefit of GPIs after a clopidogrel loading dose 
of 600 mg, they should only be used in bail-out situations or 
at the discretion of the operator when PCI is performed in 
complex lesions.14
2 .  n o n - s T  E l E va T I o n  a C s
In the era before dual antiplatelet therapy, trials of ad-
equately dosed GPIs in patients undergoing balloon angio-
plasty and coronary stent implantation demonstrated a lower 
incidence of composite ischemic events in favor of GPIs in 
combination with heparin, than with heparin alone, primarily 
through a reduction in MI.9 In the ISAR-REACT 2 trial, this 
benefit was maintained despite clopidogrel pretreatment with 
a loading dose of 600 mg in patients with non ST-segment 
elevation MI (13.1% vs. 18.3%, p=0.02), but not in those with 
unstable angina (4.6% vs. 4.6%, p=0.98).18
The ACUITy trial compared a regimen of bivalirudin 
alone (with bail-out GPI in 7.4%) against heparin plus GPI 
and found a significant benefit of bivalirudin alone with respect 
to the primary 30-day composite endpoint of ischemic and 
bleeding complications (10.1% vs. 11.7%; p=0.02), driven by 
a reduction in major bleeding complications (3.0% vs 5.7%, 
respectively; p=0.001) without a significant increase in is-
chemic complications (7.8% vs. 7.3%, p=0.32).25 This benefit 
of bivalirudin was found regardless of downstream or upstream 
GPI use and was maintained during 1-year follow-up.46
The more recent ISAR-REACT 4 trial in PCI patients with 
non ST-segment elevation MI did not find a significant benefit 
of heparin with abciximab compared with bivalirudin alone. 
The primary endpoint of death, re-infarcion, urgent target ves-
sel revascularization, or major bleeding within 30 days occurred 
in 10.9% of patients in the heparin plus abciximab group, as 
opposed to 11.0% in the bivalirudin group (p=0.94). However, 
heparin plus abciximab was associated with significantly more 
major bleeding than bivalirudin (4.6% vs. 2.6%, p=0.02).26
Consistent with ACUITy and ISAR-REACT 4, the 
EARLy-ACS trial did not confirm a benefit in death or MI at 
30 days from routine early versus provisional late eptifibatide, 
while routine early eptifibatide was associated with a higher 
bleeding risk (TIMI major hemorrhage 2.6% vs. 1.8%, respec-
tively, p=0.02).7 In TRITON-TIMI 38, 7414 patients (54.5% 
of the total study population) received GPIs and, in terms of 
reducing the risk of cardiovascular death, MI or stroke, a con-
sistent advantage was observed from prasugrel when compared 
with clopidogrel, irrespective of the use of GPIs. The risk of 
TIMI major or minor bleeding was not significantly different 
with either prasugrel or clopidogrel, regardless of whether 
or not patients were treated with GPIs.47 Overall, there is no 
evidence for an additional benefit of routine upstream use of 
a GPI in NSTE-ACS patients scheduled for coronary angiog-
raphy and the recent guidelines recommend downstream GPI 
use in the catheterization laboratory for bail-out situations.14 
The use of bivalirudin preserves the option for bail-out gly-
coprotein IIb/IIIa inhibition.26 However, in lower-risk patients 
pre-treated with clopidogrel, bivalirudin does not appear to 
offer an advantage over heparin.24 It should be reemphasized 
that most of the evidence in support of bivalirudin is derived 
from trials in which the comparator was heparin plus GPIs, a 
combination that is no longer routinely applied.
Ticagrelor (in all NSTE-ACS patients) and prasugrel (in 
high-risk patients referred for PCI after the coronary anatomy 
is known) are now recommended over clopidogrel based on 
the above mentioned data from PLATO and TRITON-TIMI 
38 studies. Whether there is only residual benefit of GPIs with 
the increasing use of new antiplatelet agents, such as prasugrel 
or ticagrelor in NSTE-ACS, is under discussion but has not 
been addressed so far in a specific randomized controlled trial.
3 .  s t e m I
Several trials, performed before the use of pre-loading with 
clopidogrel and mostly using abciximab, documented clinical 
benefits from GPIs as adjunct to primary PCI performed with 
heparin.48-51 Of note, a significant 1-year survival benefit was 
demonstrated in a meta-analysis of GPIs with abciximab.19 
With respect to the use of GPIs in acute STEMI patients 
referred for primary PCI, the best data exist for the use of ab-
ciximab (0.25 mg/kg IV bolus followed by infusion of 0.125 μg/
kg/min up to a maximum of 10 μg/min for 12 h) in combination 
with heparin.14,21 A meta-analysis by Gurm et al evaluated for 
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differences in clinical outcome between small-molecule GPIs 
and abciximab in patients with STEMI undergoing primary 
PCI.52 Five randomized trials (n=2138 patients) comparing 
tirofiban or eptifibatide with abciximab as an adjunctive 
therapy to primary PCI were included in this meta-analysis. 
There were no differences in 30-day mortality, re-infarction 
or major bleeding between the two adjunctive strategies.52 
Thus, and according to the most recent guidelines for STEMI 
management and revascularization, abciximab, eptifibatide or 
tirofiban can be used in primary PCI for STEMI.14,21
Similar to NSTE-ACS, the upstream use of GPIs is not 
recommended in the present guidelines, because the only 
prospective randomized trial investigating the pre- vs in-cath 
lab use of abciximab (FINESSE trial) was negative with respect 
to hard clinical endpoints.22 In contrast, based upon meta-
analyses, registries, large post hoc analyses and the OnTIME 
II trial, it has been possible to demonstrate a benefit of early 
use of abciximab, particularly in patients that contacted rap-
idly the health care system (diagnosed and treated less than 3 
hours from the onset of pain).53-57 This is why upstream use of 
GPIs has regained a weak recommendation (IIb) in the last 
STEMI guidelines.21
Although GPIs are approved for intravenous use, several 
studies have assessed the efficacy of intracoronary adminis-
tration in patients with STEMI undergoing primary PCI. A 
meta-analysis of small-sample studies suggests a benefit of in-
tracoronary use of GPIs.58 In the INFUSE-AMI trial, intracor-
onary abciximab delivered through a specialized drug-delivery 
catheter reduced infarct size compared with no abciximab in 
452 patients with large, anterior STEMI undergoing primary 
PCI.59 However, this finding was not supported by the large 
AIDA-STEMI trial. In this trial, a total of 2065 patients with 
STEMI undergoing primary PCI were randomly assigned to 
an intracoronary or intravenous abciximab bolus during the 
PCI procedure, followed by an intravenous infusion. No dif-
ference was found between groups in the primary end point 
of all-cause mortality, recurrent MI, or new congestive heart 
failure at 90 days, nor were there any significant differences 
in the secondary end points of early ST-segment resolution, 
TIMI flow grade, or enzymatic infarct size.60 
based on the HORIZON-AMI study, bivalirudin mono-
therapy has been shown to be a better alternative compared 
to heparin plus GPI in patients with acute STEMI referred for 
primary PCI. Ischemic events were similar between both study 
arms, but severe bleeding complications were significantly 
reduced under bivalirudin.27 As a consequence, short- and 
long-term mortality was statistically reduced, which cannot be 
explained by the reduction of bleeding alone, but was the main 
trigger for a strong guideline recommendation of bivalirudin 
in this indication.14,28 However, as analyzed above, this mor-
tality benefit was not replicated in studies and meta-analyses 
that followed, while the advantages of bivalirudin regarding 
bleeding complications prevention seems to fade when the 
comparator is heparin with provisional and not routine GPI use 
and furthermore if most current practices with other bleeding 
prevention strategies are applied during PCI.29,31-33,36,61 This is 
why in the latest revascularization guidelines, heparin plus 
planned or provisional GPI holds a class I recommendation, 
while bivalirudin holds a class IIa recommendation for primary 
PCI.14 As for patients with stable CAD or NSTE-ACS under-
going PCI, current guidelines strongly recommend the use of 
GPIs during primary PCI for STEMI for bail-out or evidence 
of thrombotic complication or no-reflow.14 An example of GPI 
use for bail-out in a primary PCI procedure for STEMI due 
to subacute stent thrombosis with massive thrombus burden 
is shown in Figures 2 and 3. 
Prasugrel and ticagrelor have replaced clopidogrel as the 
first choice therapy in STEMI.14,21 Clopidogrel, but not prasu-
grel and ticagrelor was used before in randomized studies of 
primary PCI for STEMI comparing bivalirudin to heparin 
with or without use of GPIs. However, like clopidogrel these 
agents also have delayed absorption in STEMI, and the type 
of P2y12 inhibitor used did not affect the relative safety or 
efficacy profile of bivalirudin versus heparin with or without 
GPIs inhibitors in the EUROMAX trial.29,62
With the new fast-acting and highly effective antiplatelet 
drugs such as prasugrel or ticagrelor a strategy of early use 
of GPIs seems less promising, although this has not been ad-
equately investigated up to now. However, as recently shown, 
the early use of prasugrel or ticagrelor might not sufficiently 
inhibit platelet activity at the time when primary PCI is actually 
performed.62 Accordingly, primary PCI outcomes might be im-
proved by appropriately administered intravenous antiplatelet 
therapy with GPIs as shown in the FAbOLOUS PRO study. 
This study has shown that with prasugrel administration, the 
inhibition of platelet aggregation is suboptimal for at least 2 
hours in STEMI patients, but when given in association with 
a bolus only of tirofiban (25 μg/kg in 3 minutes), sufficient 
inhibition of platelet aggregation is obtained without residual 
variability after treatment, which makes a post-bolus tirofiban 
infusion unnecessary.63
Cangrelor, which is expected to be available soon for 
clinical use, is an intravenous, potent, rapidly acting P2y12 
receptor inhibitor that has been evaluated in several phase 
III studies involving over 25,000 patients undergoing PCI for 
stable CAD or ACS and might prove to be a game changer. 
In the CHAMPION-PHOENIX trial, which included stable 
patients as well as NSTE-ACS and STEMI patients, can-
grelor (bolus 30 mg/kg, infusion 4 mg/kg/min) compared to 
clopidogrel (loading dose of 300 mg or 600 mg) reduced the 
rate of ischemic events, including stent thrombosis, with-
out a significant increase in severe bleeding.64,65 A pooled 
analysis of patient-level data from the three major cangrelor 
trials (CHAMPION-PCI, CHAMPION-PLATFORM, and 
CHAMPION-PHOENIX) confirmed the lower rates of PCI 
peri-procedural thrombotic complications (3.8% for cangrelor 
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vs 4.7% for clopidogrel, p=0.0007) and of stent thrombosis 
(0.5% vs 0.8%, respectively, p=0.0008) with no difference in 
major bleeding.64 These early benefits were maintained at 30 
days with consistency across all patient subgroups. There was 
no correlation between treatment effect and clinical presenta-
tion and there was a significant lower incidence of Q-wave 
MI in favor of cangrelor. Altogether, cangrelor seems to be 
a good therapeutic option in P2y12 inhibitor-naive patients 
undergoing PCI, although data showed no effect on mortal-
ity and benefits that are mainly derived from preventing 
intra-procedural stent thrombosis.64 In general, cangrelor, 
with its fast on/off effect (half-life 3 min), seems superior to 
clopidogrel when preloading is not possible, promises rapid 
and sufficient inhibition of platelet inhibition among patients 
with STEMI treated with primary PCI, but it has so far not 
been compared against prasugrel, ticagrelor, or GPIs. Con-
ceptually, however, it is expected to further challenge the role 
that GPIs still hold in STEMI treatment.
FIgUre 2. A case example of glycoprotein IIb/IIIa inhibitor (GPI) use for bail-out because of heavy thrombus (procedure 1): 1. 
Acute myocardial infarction due to subacute stent thrombosis in a dominant circumflex artery (LCx) just proximal to the level of 
the origin of the first obtuse marginal branch (OM1). Five days earlier the 58-year-old male patient had been hospitalized because 
of NSTE-ACS, pretreated with aspirin and clopidogrel 600 mg loading dose and treated with PCI under bivalirudin anticoagulation 
with implantation of two stents to treat a sub-occlusive (95-99%) lesion of the LCx at the level of the OM1. Two stents were implanted 
in the initial PCI: the first 3x15 mm was implanted directly in LCx (jailing the OM1 ostium) and a second 3x9 mm was added with 
minimal overlap just distally (because of edge-dissection and slow-flow after implanting the first), to terminate a PCI procedure 
without application of any bifurcation technique. 2-5. The patient was treated with multiple manual thrombectomy runs (10) that did 
not retrieve much of the massive thrombus which gradually “melted” during a long procedure after the administration of abciximab 
intracoronary bolus and infusion. 6. Final result: TIMI III flow was restored despite some residual thrombus at the bifurcation. No 
balloon dilation or stent implantation was performed. A stent visualization enhancement technique (StentViz) showed that the 
stents were well expanded, but with somehow irregular borders at the most proximal part. Abciximab infusion was continued for 12 
hours, the patient was switched from clopidogrel to prasugrel, remained under therapeutic anticoagulation with enoxaparin and a 
new procedure under optical coherence tomography (OCT) guidance was scheduled 8 days later in order to address the issues at the 
LCx- OM1 bifurcation (continued in Figure 3).
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c O N c l U s I O N
GPIs provide superior protection against ischemic events in 
patients undergoing PCI for all indications and are particularly 
useful and strongly recommended in bail-out situations and 
patients at high risk for ischemic events (Table 2). However, 
bleeding is undoubtedly increased with GPIs and alternative 
approaches exist. bivalirudin is not less effective and holds a 
safety advantage over heparin and routine GPI, but in recently 
published studies it does not hold a clear safety advantage over 
heparin with provisional GPI use, especially when other bleed-
FIgUre 3. A case example of GPI use for bail-out (continued, procedure 2): 1. No more angiographic evidence of thrombus but 
severe stenosis remains at the OM1 ostium, which is jailed by the LCx stent. by OCT examination, it becomes evident that the LCx 
stent part proximal to the OM1 ostium has irregular contour and is underexpanded as well as undersized (mean diameter 2.56 mm 
and stent area 5.25 mm² for a 3 mm stent in an artery with a proximal reference diameter of 3.5 mm). 2. After gaining guidewire ac-
cess to the OM1, a kissing balloon inflation at the LCx-OM1 bifurcation is performed with 3x12 mm and 2.5x12 mm non-compliant 
balloons respectively. 3. A 2.5x19 mm stent is implanted at the ostial-proximal OM1 lesion with minimal protrusion into the LCx. 
4. A 3.5x15 mm non-compliant balloon inflation in the LCx, in front of the OM1 ostium, creates a mini-crush to the protruding part 
of the OM1 stent. 5. Final kissing at the LCx-OM1 bifurcation with two non-compliant balloons, a 3x12 mm (LCx) and a 2.5x12 mm 
(OM1). 6. Optimal final angiographic result. At OCT control the initially irregular, underexpanded and undersized proximal stent 
part is now corrected and well apposed with increased mean diameter (from 2.56 mm to 3.57 mm) and increased lumen and stent 
area (from 5.25 mm² to 10.16 mm²).
tAble 2. Situations where use of glucoprotein IIb/IIIa 
inhibitors is advocated or should be considered.
Heavy thrombotic burden
Intra-procedural thrombus formation
Slow flow / no-reflow
Threatened vessel closure
No preloading with P2y12 antagonists
Complex lesions / High risk patients
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ing prevention measures are taken, such as radial approach and 
not very high heparin doses combined with ACT monitoring. 
It is not wise to derive a universal recommendation concern-
ing the use of GPIs on the basis of the data. Rather, it would 
appear prudent to reserve GPI use for patients who are at high 
risk of early ischemic complications and for already heparin 
treated patients. On the other hand, in patients for whom the 
short-term risk of major bleeding is predominant, avoidance 
of GPIs and preference for bivalirudin over heparin, unless 
faced with extreme thrombotic risk, would be reasonable. 
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